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Abstract
Since the production of peroxynitrite may contribute to the pathophysiology of endotoxemia or sepsis, the quantities of
 .the produced peroxynitrite were evaluated in rats after lipopolysaccharide LPS treatment by measuring plasma nitrotyro-
sine concentrations with a new method. The intraperitoneal administration of LPS caused a persistent increase in plasma
 y1 .nitrotyrosine concentrations, which reached a maximum with 6-fold level of the base line 105 pmol ml at 24 h and
gradually declined to 3-fold level of the base line at 7 days. However, plasma concentrations of nitrite and nitrate peaked at
18 h, returning to base line within 48 h. The effect of LPS on the increase in plasma concentration of nitrotyrosine was
dose-dependent and consistent with that of nitrite and nitrate concentrations. On the other hand, intravenous injection of
nitrotyrosine revealed a rapid clearance with a plasma half-life of 1.67 h. These results indicate that the elevation of plasma
nitrotyrosine concentrations may persist for more than a week after LPS treatment, and that the determination of plasma
nitrotyrosine concentrations may be useful to detect the previous peroxynitrite-dependent oxidative damages. q 1997
Elsevier Science B.V.
Keywords: Nitrotyrosine; Lipopolysaccharide; Nitrate; Nitrite; Peroxynitrite; Endotoxemia
1. Introduction
 .Nitric oxide NO is a short-lived cytotoxic media-
tor that has been implicated in the pathogenesis of
wendotoxin-induced tissue injury and septic shock 1–
x3 . Administration with bacterially derived lipopoly-
 .saccharide LPS causes the induction of nitric oxide
 .synthase isoform type II , resulting in the production
of large quantities of NO in many cells including
w xmacrophage and vascular smooth muscle 4–6 . The
 y.subsequent interaction of NO with superoxide O2
) Corresponding author. Tel.: q81-859-348014; fax: q81-
859-348140.
 y.forms peroxynitrite ONOO , a powerful oxidant
capable of causing pathological damages in condi-
tions such as endotoxemia or sepsis, inflammation,
w xatherosclerosis, and ischemia-reperfusion 7–11 . Per-
oxynitrite can decompose to give various products
that nitrate aromatic amino acids existing as free
forms or components of proteins. Nitration on the
ortho position of tyrosine is a major reaction. There-
fore, the plasma concentration of nitrotyrosine NO –2
. Tyr may reflect the degree of peroxynitrite NO and
.superoxide -dependent damages around vascular tis-
sues, since it is difficult to demonstrate the other
w xoxidative products of peroxynitrite 7–10,12,13 .
However, there is a possibility that plasma tyrosine
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may be nitrated by the peroxidase–hydrogen perox-
w xide system during inflammatory processes 14 .
Although the elevated plasma levels of NO –Tyr2
in patients of rheumatoid arthritis were detected by
reversed-phase high-performance liquid chromatogra-
 .phy HPLC with a direct measurement of its own
 .ultraviolet absorbance 274 nm , normal levels of
NO –Tyr in human plasma were below the detection2
w xlimit of 0.2 mM 7,8 . Thus, we have developed a
highly sensitive and simple HPLC method for deter-
mination of plasma concentrations of NO –Tyr with2
a precolumn derivatization of the amino acid by
 .4-fluoro-7-nitrobenzo-2-oxa-1,3-diazole NBD-F
w x15 .
Therefore, in the present experiments, we investi-
gated time- and dose-dependent alterations of plasma
NO –Tyr concentrations after LPS treatments in rats,2
compared to the changes in plasma concentrations of
nitrite and nitrate the stable oxidation products of
.NO , in order to clarify whether plasma NO –Tyr2
concentration may be an useful marker for peroxyni-
 .trite NO and superoxide -dependent tissue damages.
2. Materials and methods
2.1. Chemicals
 .Lipopolysaccharide serotype 055:B5 , 3-nitro-L-
 .tyrosine NO –Tyr and a-methyl-L-p-tyrosine were2
 .purchased from Sigma St. Louis, MO . 4-Fluoro-7-
 .nitrobenzo-2-oxa-1,3-diazole NBD-F was from Do-
 .jindo Kumamoto, Japan . Other chemicals were of
analytical reagent grade and obtained from Wako
 .  .Osaka , Cica-Merck Tokyo and companies listed
above.
2.2. LPS treatment and sample preparation
 .Male Wistar rats 200–250 g were obtained from
 .SLC Shizuoka, Japan and allowed to acclimate to
their surroundings for 1 week before experiments.
The experiments were conducted in the accordance
with the guideline for animal experimentation in Fac-
ulty of Medicine, Tottori University. LPS was dis-
solved in the sterile saline and administered intraperi-
toneally into rats at a dose of 10 mg kgy1 of the body
weight or the designated dose. Under pentobarbital
 y1.  .anesthesia 50 mg kg , blood samples ca. 200 ml
were obtained by cardiac puncture 15 h or the indi-
cated time after the LPS treatment and collected in
 y1.microfuge tubes containing heparin 40 U ml . A
 . part of plasma 60 ml was mixed with ethanol 140
.  .ml containing methyltyrosine 150 pmol , as an in-
ternal standard. After the centrifugation at 10000=g
for 10 min, the resulting supernatant was kept at
y808C until the chromatographic analysis for NO –2
Tyr. The remaining plasma was used for assay of
nitrite and nitrate concentrations.
In a clearance experiment, authentic NO –Tyr 7.22
y1.mmol kg was intravenously given into rats from a
tail vein. Blood samples were taken 3, 6, 12, 24, and
36 h after the injection, and treated as described
above.
2.3. Determination of plasma concentrations of
NO –Tyr, nitrite and nitrate2
Plasma NO –Tyr concentrations were determined2
w xas described previously 15 . Briefly, the stored sam-
 .  .ples 100 ml were derivatized with NBD-F 1 mg in
 .0.1 M sodium borate buffer pH 8.7 at 608C for 2
min. After the addition of 0.1 M HCl, aliquot 100
.ml was injected onto a reversed-phase column
 .Wakosil 5C18, 250=4.6 mm ID, Wako , which
was eluted with 0.1 M sodium phosphate buffer pH
.  .7.2 : methanol 45:55, vrv . Calculation of NO –Tyr2
concentration in each sample was based on the ratio
of the fluorescent intensity of NO –Tyr to that of2
methyltyrosine, an internal standard. The values are
expressed as pmol per ml of plasma.
Plasma nitrite and nitrate concentrations were col-
orimetrically determined by using the Griess reaction
of a nitrite–nitrate assay kit-C Dojindo, Kumamoto,
.Japan according to the attached literature. Total NOx
 .nitrite and nitrate and nitrite concentrations were
obtained with and without the treatment of nitrate
reductase, respectively. Nitrate concentrations were
w x w xcalculated from the equation nitrate s total NOx
w x.y nitrite . The concentrations are expressed as nmol
per ml of plasma.
2.4. Statistical analysis
The result of the experiments is expressed as the
mean"SD. For the statistical analysis, Tukey’s test
( )Y. Kamisaki et al.rBiochimica et Biophysica Acta 1362 1997 24–2826
was adopted to compare the source of data obtained
from multiple groups after ANOVA was performed.
Differences were considered significant when P val-
ues were smaller than 0.05.
3. Results and discussion
3.1. Time-dependent effects of LPS treatment
 y1.Administration of LPS 10 mg kg elicited a
persistent increase in plasma NO –Tyr concentra-2
tions in rats. The plasma NO –Tyr concentration2
increased by 4–5 fold over the first 48 h, and gradu-
ally declined to the level of 3-fold of the basal level
 y1.105"37 pmol ml at 7 days after the LPS treat-
 .ment Fig. 1A . The basal concentration of NO –Tyr2
corresponded to ca. 0.1% of the plasma tyrosine
levels in rats. The elevations of NO –Tyr concentra-2
 .tions were significant P-0.01 at any time after
LPS treatment, compared to the basal level. How-
ever, the increase in plasma NO concentration wasx
transient. The plasma NO concentration peaked atx
12 h, returning to the base line 54.1"22.6 nmol
Fig. 1. Time course of plasma concentrations of nitrotyrosine
 .  .NO –Tyr and total nitrite and nitrate NO after lipopoly-2 x
 .  y1.saccharide LPS treatment. LPS 10 mg kg was administered
intraperitoneally into rats at time zero, followed by determining
 .plasma concentrations of NO –Tyr panel A and total NO2 x
 .panel B at the designated times using HPLC and the Griess
reaction, respectively. Data are expressed as the mean"SD;
ns4–9.
Fig. 2. Time course of LPS-induced increases in plasma concen-
 .  .trations of nitrite circles and nitrate squares in rats. After LPS
injection, plasma concentrations of nitrite and total NO werex
measured by the Griess reaction without and with nitrate reduc-
tase-treatment, respectively. Nitrate concentrations were calcu-
lated by the subtraction of nitrite from the total NO . Data arex
expressed as the mean"SD; ns4–9.
y1.  .ml within 48 h after Fig. 1B . As shown in Fig.
w x w x 2, nitrite comprised 20 to 30% of total NO thex
w x.remainder being nitrate .
3.2. Dose-dependent effects of LPS treatment
In order to detect the maximum effects on plasma
concentrations of both NO –Tyr and NO , blood was2 x
taken 15 h after LPS administration at a dose of 0, 1,
3.16, or 10 mg kgy1. Fig. 3 shows approximately
parallel effects of LPS on both plasma concentra-
tions, although their effects were not saturated due to
the toxicity of LPS. The data indicate that NO –Tyr2
Fig. 3. Dose-dependent effects of LPS on plasma concentrations
of NO –Tyr and total NO . 15 h after the injection of LPS 0–102 x
y1.  .mg kg , plasma concentrations of NO –Tyr open columns2
 .and total NO shaded columns were determined. Data arex
expressed as the mean"SD; ns4–6. )P -0.05, ))P -0.01
 y1.compared with that of vehicle treatment LPS, 0 mg kg .
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and NO may be derived from the same substancex
that LPS treatment produced through the increase in
NO from the induced NO synthase in various cells
w x4–6 . Since bacterial toxins stimulate leukocytes to
generate superoxide radicals in addition to NO, a part
of the generated NO reacts with superoxide anions to
produce peroxynitrite, which subsequently nitrate ty-
rosine existing as a free from or protein-residue
w x7,12,13 . Therefore, it is necessary to clarify whether
the discrepant results during elimination phases of
NO –Tyr and NO may be attributed to the differ-2 x
ences in their clearance rates in plasma.
3.3. Clearance of NO –Tyr in plasma2
In order to investigate a clearance rate of NO –Tyr2
in rat plasma, the plasma concentrations were mea-
sured after intravenous injection of authentic NO –2
 y1.Tyr 7.2 mmol kg . Pharmacokinetic analysis of
data in Fig. 4 revealed that the plasma half-life of
NO –Tyr was 1.67"0.17 h, which is consistent with2
those of physiological amino acids and amino acid-
wrelated drugs such as levodopa and methyldopa 16–
x18 . However, plasma NO –Tyr concentrations dur-2
 .ing the declining phase Fig. 1A indicate that NO –2
Tyr is eliminated from rat plasma with a half-life of
7.8"0.7 days, which is similar to those of plasma
 . w xproteins such as albumin 1–2 weeks 19,20 . Since
peroxynitrite gives adducts of nitro group to tyrosine
residues in proteins, in addition to free tyrosine, the
Fig. 4. Plasma clearance of NO –Tyr. After NO –Tyr 7.22 2
y1.mmol kg was intravenously given into rats, the plasma con-
centrations were determined at the indicated time. Data are
expressed as the mean"SD; ns8. Each pharmacokinetic analy-
 .sis demonstrated the plasma half-life 1.67"0.17 h and distribu-
 y1.tion volume 0.386"0.060 l kg of NO –Tyr.2
degradation of nitrated plasma proteins may explain
the delayed clearance of plasma NO –Tyr. However,2
nitrated proteins are reported to be degraded more
w xrapidly than non-nitrated proteins 21 . Moreover,
there is a possibility that the elimination system of
plasma NO –Tyr may be disturbed by the LPS treat-2
ment. Therefore, the persisted elevation of plasma
NO –Tyr concentrations after LPS treatment may be2
due to continuous supplement from the degradation
of nitrated plasma proteins and due to the slow
clearance induced by the oxidative stress, although
further experiments are necessary to clarify the mech-
anism.
3.4. Conclusion
Although plasma NO –Tyr is formed not only by2
peroxynitrite-dependent mechanism but also by the
oxidation of nitrite through peroxidase–hydrogen
w xperoxide system 14 , it is accepted that NO –Tyr is2
produced during the peroxynitrite-dependent oxida-
tion processes such as endotoxemia or sepsis, inflam-
wmation, atherosclerosis, and ischemia-reperfusion 7–
x11 . In addition, the existence of plasma metabolite of
NO –Tyr may indicate that the plasma concentration2
of NO –Tyr may not reflect the whole nitration2
w xproducts derived from peroxynitrite 22,23 . There-
fore, the present results suggest that a single treat-
ment of LPS causes a sustained increase in plasma
NO –Tyr for more than a week, although plasma2
NO returned to the basal level within 48 h, and thatx
the measurement of plasma NO –Tyr concentration2
may be useful for the past evidence of peroxynitrite
 .NO and superoxide -dependent oxidation stress in-
cluding endotoxemia or sepsis.
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